These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7709863)

  • 1. Differences in the lymphoproliferative pattern to Leishmania mexicana antigens recognized by immunized and infected mice.
    Correnti M; Ortega G
    Acta Trop; 1994 Dec; 58(3-4):243-53. PubMed ID: 7709863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NKT cell activation by Leishmania mexicana LPG: Description of a novel pathway.
    Zamora-Chimal J; Fernández-Figueroa EA; Ruiz-Remigio A; Wilkins-Rodríguez AA; Delgado-Domínguez J; Salaiza-Suazo N; Gutiérrez-Kobeh L; Becker I
    Immunobiology; 2017 Feb; 222(2):454-462. PubMed ID: 27523746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice.
    Rosas LE; Keiser T; Barbi J; Satoskar AA; Septer A; Kaczmarek J; Lezama-Davila CM; Satoskar AR
    Int Immunol; 2005 Oct; 17(10):1347-57. PubMed ID: 16141242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis.
    Pinto EF; de Mello Cortezia M; Rossi-Bergmann B
    Vaccine; 2003 Sep; 21(25-26):3534-41. PubMed ID: 12922080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell responses to immunodominant LACK antigen do not play a critical role in determining susceptibility of BALB/c mice to Leishmania mexicana.
    Torrentera FA; Glaichenhaus N; Laman JD; Carlier Y
    Infect Immun; 2001 Jan; 69(1):617-21. PubMed ID: 11119565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Determination of the specificity of seric IgA produced in response to antigens of Leishmania (Leishmania) mexicana in murine leishmaniasis].
    Pérez-Aguilar MC; Hernández O; Maizo de Segnini Z; Rojas CH; Díaz S; Alarcón M; Goncalves L
    Invest Clin; 2011 Sep; 52(3):216-29. PubMed ID: 21950193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute cysticercosis favours rapid and more severe lesions caused by Leishmania major and Leishmania mexicana infection, a role for alternatively activated macrophages.
    Rodríguez-Sosa M; Rivera-Montoya I; Espinoza A; Romero-Grijalva M; López-Flores R; González J; Terrazas LI
    Cell Immunol; 2006 Aug; 242(2):61-71. PubMed ID: 17118349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoregulatory pathways in murine leishmaniasis: different regulatory control during Leishmania mexicana mexicana and Leishmania major infections.
    Alexander J; Kaye PM
    Clin Exp Immunol; 1985 Sep; 61(3):674-82. PubMed ID: 3907906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of a Salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana.
    González CR; Noriega FR; Huerta S; Santiago A; Vega M; Paniagua J; Ortiz-Navarrete V; Isibasi A; Levine MM
    Vaccine; 1998; 16(9-10):1043-52. PubMed ID: 9682357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partial protective responses induced by a recombinant cysteine proteinase from Leishmania (Leishmania) amazonensis in a murine model of cutaneous leishmaniasis.
    Fedeli CE; Ferreira JH; Mussalem JS; Longo-Maugéri IM; Gentil LG; dos Santos MR; Katz S; Barbiéri CL
    Exp Parasitol; 2010 Feb; 124(2):153-8. PubMed ID: 19735658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
    Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
    Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes.
    Russell DG; Alexander J
    J Immunol; 1988 Feb; 140(4):1274-9. PubMed ID: 3257774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-lymphocytes in experimental Leishmania amazonensis infection: comparison between immunized and naive BALB/c mice.
    Pompeu M; Freitas AL; dosReis GA; Barral-Netto M
    Parasitol Res; 1992; 78(1):16-22. PubMed ID: 1584741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SCID mice reconstituted with IL-4-deficient lymphocytes, but not immunocompetent lymphocytes, are resistant to cutaneous leishmaniasis.
    Satoskar A; Brombacher F; Dai WJ; McInnes I; Liew FY; Alexander J; Walker W
    J Immunol; 1997 Nov; 159(10):5005-13. PubMed ID: 9366428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptor 2 (TLR2) plays a role in controlling cutaneous leishmaniasis in vivo, but does not require activation by parasite lipophosphoglycan.
    Halliday A; Bates PA; Chance ML; Taylor MJ
    Parasit Vectors; 2016 Oct; 9(1):532. PubMed ID: 27716391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular and humoral immunity to Leishmania major in genetically susceptible mice after in vivo depletion of L3T4+ T cells.
    Sadick MD; Heinzel FP; Shigekane VM; Fisher WL; Locksley RM
    J Immunol; 1987 Aug; 139(4):1303-9. PubMed ID: 3112230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leishmania amazonensis: humoral response to amastigote excreted-antigens in murine leishmaniasis.
    Hernández-Chinea C
    Exp Parasitol; 2007 Aug; 116(4):492-6. PubMed ID: 17349625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in response to Leishmania antigens in vitro.
    Sadick MD; Locksley RM; Tubbs C; Raff HV
    J Immunol; 1986 Jan; 136(2):655-61. PubMed ID: 3079789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of TLR9 on Leishmania amazonensis infection and its influence on intranasal LaAg vaccine efficacy.
    Pratti JES; da Fonseca Martins AM; da Silva JP; Ramos TD; Pereira JC; Firmino-Cruz L; Oliveira-Maciel D; Vieira TSS; Lacerda LL; Vale AM; Freire-de-Lima CG; Gomes DCO; Saraiva EM; Rossi-Bergmann B; de Matos Guedes HL
    PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007146. PubMed ID: 30802247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cellular immune response to a purified antigen from Leishmania mexicana subsp. amazonensis enhances the size of the leishmanial lesion on susceptible mice.
    Rodrigues MM; Mendonça-Previato L; Charlab R; Barcinski MA
    Infect Immun; 1987 Dec; 55(12):3142-8. PubMed ID: 3500131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.